Corticotropin releasing factor-induced CREB activation in striatal neurons occurs via a novel gβγ signaling pathway

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Stern, Christopher M ^a   Luoma, Jessie I ^a   Meitzen, John ^a   Mermelstein, Paul G ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 AMINO 5 PHOSPHONOVALERIC ACID; 9 (TETRAHYDRO 2 FURYL)ADENINE; ANTISAUVAGINE 30; ASTRESSIN; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; CYCLIC AMP; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ETHYLENE GLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID; FORSKOLIN; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; GUANINE NUCLEOTIDE BINDING PROTEIN GAMMA SUBUNIT; MITOGEN ACTIVATED PROTEIN KINASE; N [2 [[N [3 (4 CHLOROPHENYL) 2 PROPENYL] N METHYLAMINO]METHYL]PHENYL] N (2 HYDROXYETHYL) 4 METHOXYBENZENESULFONAMIDE; NIFEDIPINE; TETRODOTOXIN; ADENYLATE CYCLASE; CALCIUM; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CRF RECEPTOR TYPE 1; CYCLIC AMP DEPENDENT PROTEIN KINASE; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; CELL FUNCTION; CELLULAR STRESS RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME ACTIVATION; INTRACELLULAR SIGNALING; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; TRANSCRIPTION INITIATION; ANIMAL; BIOLOGICAL MODEL; CYTOLOGY; DRUG EFFECT; ENZYMOLOGY; METABOLISM; NEOSTRIATUM; NERVE CELL; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ADENYLATE CYCLASE; ANIMALS; CALCIUM; CORTICOTROPIN-RELEASING HORMONE; CYCLIC AMP; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLIC AMP-DEPENDENT PROTEIN KINASES; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; GTP-BINDING PROTEIN BETA SUBUNITS; GTP-BINDING PROTEIN GAMMA SUBUNITS; MAP KINASE SIGNALING SYSTEM; MODELS, BIOLOGICAL; NEOSTRIATUM; NEURONS; PHOSPHORYLATION; RATS; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; SIGNAL TRANSDUCTION;

EID: 79952938773     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018114     Document Type: Article

References (88)

1. Sarnyai Z, (1998) Neurobiology of stress and cocaine addiction. Studies on corticotropin-releasing factor in rats, monkeys, and humans. Ann N Y Acad Sci 851: 371-387.
2. Brown SA, Vik PW, Patterson TL, Grant I, Schuckit MA, (1995) Stress, vulnerability and adult alcohol relapse. J Stud Alcohol 56: 538-545.
3. Cleck JN, Blendy JA, (2008) Making a bad thing worse: adverse effects of stress on drug addiction. J Clin Invest 118: 454-461.
4. Shaham Y, Erb S, Stewart J, (2000) Stress-induced relapse to heroin and cocaine seeking in rats: a review. Brain Res Brain Res Rev 33: 13-33.
5. Goeders NE, Guerin GF, (1994) Non-contingent electric footshock facilitates the acquisition of intravenous cocaine self-administration in rats. Psychopharmacology (Berl) 114: 63-70.
6. Haney M, Maccari S, Le Moal M, Simon H, Piazza PV, (1995) Social stress increases the acquisition of cocaine self-administration in male and female rats. Brain Res 698: 46-52.
7. Miczek KA, Mutschler NH, (1996) Activational effects of social stress on IV cocaine self-administration in rats. Psychopharmacology (Berl) 128: 256-264.
8. Ramsey NF, Van Ree JM, (1993) Emotional but not physical stress enhances intravenous cocaine self-administration in drug-naive rats. Brain Res 608: 216-222.
9. Shaham Y, Stewart J, (1994) Exposure to mild stress enhances the reinforcing efficacy of intravenous heroin self-administration in rats. Psychopharmacology (Berl) 114: 523-527.
10. Piazza PV, Le Moal M, (1998) The role of stress in drug self-administration. Trends Pharmacol Sci 19: 67-74.
11. Kreibich AS, Briand L, Cleck JN, Ecke L, Rice KC, et al. (2009) Stress-induced potentiation of cocaine reward: a role for CRF R1 and CREB. Neuropsychopharmacology 34: 2609-2617.
12. Carlezon WA Jr, Thome J, Olson VG, Lane-Ladd SB, Brodkin ES, et al. (1998) Regulation of cocaine reward by CREB. Science 282: 2272-2275.
13. Nestler EJ, (2004) Molecular mechanisms of drug addiction. Neuropharmacology 47 (Suppl 1): 24-32.
14. Walters CL, Cleck JN, Kuo YC, Blendy JA, (2005) Mu-opioid receptor and CREB activation are required for nicotine reward. Neuron 46: 933-943.
15. Dinieri JA, Nemeth CL, Parsegian A, Carle T, Gurevich VV, et al. (2009) Altered sensitivity to rewarding and aversive drugs in mice with inducible disruption of cAMP response element-binding protein function within the nucleus accumbens. J Neurosci 29: 1855-1859.
16. Brunzell DH, Mineur YS, Neve RL, Picciotto MR, (2009) Nucleus accumbens CREB activity is necessary for nicotine conditioned place preference. Neuropsychopharmacology 34: 1993-2001.
17. Lim MM, Liu Y, Ryabinin AE, Bai Y, Wang Z, et al. (2007) CRF receptors in the nucleus accumbens modulate partner preference in prairie voles. Horm Behav 51: 508-515.
18. Pecina S, Schulkin J, Berridge KC, (2006) Nucleus accumbens corticotropin-releasing factor increases cue-triggered motivation for sucrose reward: paradoxical positive incentive effects in stress? BMC Biol 4: 8.
19. Behan DP, Khongsaly O, Owens MJ, Chung HD, Nemeroff CB, et al. (1997) Corticotropin-releasing factor (CRF), CRF-binding protein (CRF-BP), and CRF/CRF-BP complex in Alzheimer's disease and control postmortem human brain. J Neurochem 68: 2053-2060.
20. Merchenthaler I, (1984) Corticotropin releasing factor (CRF)-like immunoreactivity in the rat central nervous system. Extrahypothalamic distribution. Peptides 5 (Suppl 1): 53-69.
21. De Souza EB, Whitehouse PJ, Folstein SE, Price DL, Vale WW, (1987) Corticotropin-releasing hormone (CRH) is decreased in the basal ganglia in Huntington's disease. Brain Res 437: 355-359.
22. Guan X, Wang L, Chen CL, Guan Y, Li S, (2010) Roles of two subtypes of corticotrophin-releasing factor receptor in the corticostriatal long-term potentiation under cocaine withdrawal condition. J Neurochem 115: 795-803.
23. Chen FM, Bilezikjian LM, Perrin MH, Rivier J, Vale W, (1986) Corticotropin releasing factor receptor-mediated stimulation of adenylate cyclase activity in the rat brain. Brain Res 381: 49-57.
24. Battaglia G, Webster EL, De Souza EB, (1987) Characterization of corticotropin-releasing factor receptor-mediated adenylate cyclase activity in the rat central nervous system. Synapse 1: 572-581.
25. Hillhouse EW, Grammatopoulos DK, (2006) The molecular mechanisms underlying the regulation of the biological activity of corticotropin-releasing hormone receptors: implications for physiology and pathophysiology. Endocr Rev 27: 260-286.
26. Perrin MH, Sutton SW, Cervini LA, Rivier JE, Vale WW, (1999) Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of corticotropin-releasing factor receptors. J Pharmacol Exp Ther 288: 729-734.
27. Chalmers DT, Lovenberg TW, De Souza EB, (1995) Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression. J Neurosci 15: 6340-6350.
28. Iredale PA, Alvaro JD, Lee Y, Terwilliger R, Chen YL, et al. (2000) Role of corticotropin-releasing factor receptor-1 in opiate withdrawal. J Neurochem 74: 199-208.
29. De Souza EB, (1987) Corticotropin-releasing factor receptors in the rat central nervous system: characterization and regional distribution. J Neurosci 7: 88-100.
30. Primus RJ, Yevich E, Baltazar C, Gallager DW, (1997) Autoradiographic localization of CRF1 and CRF2 binding sites in adult rat brain. Neuropsychopharmacology 17: 308-316.
31. Davies SP, Reddy H, Caivano M, Cohen P, (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351: 95-105.
32. Lochner A, Moolman JA, (2006) The many faces of H89: a review. Cardiovasc Drug Rev 24: 261-274.
33. Meitzen J, Luoma JI, Stern CM, Mermelstein PG, (2010) beta1-adrenergic receptors activate two distinct signaling pathways in striatal neurons. J Neurochem.
34. Lonze BE, Ginty DD, (2002) Function and regulation of CREB family transcription factors in the nervous system. Neuron 35: 605-623.
35. Deisseroth K, Mermelstein PG, Xia H, Tsien RW, (2003) Signaling from synapse to nucleus: the logic behind the mechanisms. Curr Opin Neurobiol 13: 354-365.
36. Wu GY, Deisseroth K, Tsien RW, (2001) Activity-dependent CREB phosphorylation: convergence of a fast, sensitive calmodulin kinase pathway and a slow, less sensitive mitogen-activated protein kinase pathway. Proc Natl Acad Sci U S A 98: 2808-2813.
37. Lehmann DM, Seneviratne AM, Smrcka AV, (2008) Small molecule disruption of G protein beta gamma subunit signaling inhibits neutrophil chemotaxis and inflammation. Mol Pharmacol 73: 410-418.
38. Koch WJ, Hawes BE, Inglese J, Luttrell LM, Lefkowitz RJ, (1994) Cellular expression of the carboxyl terminus of a G protein-coupled receptor kinase attenuates G beta gamma-mediated signaling. J Biol Chem 269: 6193-6197.
39. Hara M, Fukui R, Hieda E, Kuroiwa M, Bateup HS, et al. (2010) Role of adrenoceptors in the regulation of dopamine/DARPP-32 signaling in neostriatal neurons. J Neurochem 113: 1046-1059.
40. Stern CM, Mermelstein PG, (2010) Caveolin regulation of neuronal intracellular signaling. Cell Mol Life Sci 67: 3785-3795.
41. Butchbach ME, Tian G, Guo H, Lin CL, (2004) Association of excitatory amino acid transporters, especially EAAT2, with cholesterol-rich lipid raft microdomains: importance for excitatory amino acid transporter localization and function. J Biol Chem 279: 34388-34396.
42. Li X, Galli T, Leu S, Wade JB, Weinman EJ, et al. (2001) Na+-H+ exchanger 3 (NHE3) is present in lipid rafts in the rabbit ileal brush border: a role for rafts in trafficking and rapid stimulation of NHE3. J Physiol 537: 537-552.
43. Bayatti N, Zschocke J, Behl C, (2003) Brain region-specific neuroprotective action and signaling of corticotropin-releasing hormone in primary neurons. Endocrinology 144: 4051-4060.
44. Refojo D, Echenique C, Muller MB, Reul JM, Deussing JM, et al. (2005) Corticotropin-releasing hormone activates ERK1/2 MAPK in specific brain areas. Proc Natl Acad Sci U S A 102: 6183-6188.
45. Blank T, Nijholt I, Grammatopoulos DK, Randeva HS, Hillhouse EW, et al. (2003) Corticotropin-releasing factor receptors couple to multiple G-proteins to activate diverse intracellular signaling pathways in mouse hippocampus: role in neuronal excitability and associative learning. J Neurosci 23: 700-707.
46. Sheng H, Zhang Y, Sun J, Gao L, Ma B, et al. (2008) Corticotropin-releasing hormone (CRH) depresses n-methyl-D-aspartate receptor-mediated current in cultured rat hippocampal neurons via CRH receptor type 1. Endocrinology 149: 1389-1398.
47. Wanat MJ, Hopf FW, Stuber GD, Phillips PE, Bonci A, (2008) Corticotropin-releasing factor increases mouse ventral tegmental area dopamine neuron firing through a protein kinase C-dependent enhancement of Ih. J Physiol 586: 2157-2170.
48. Beckstead MJ, Gantz SC, Ford CP, Stenzel-Poore MP, Phillips PE, et al. (2009) CRF enhancement of GIRK channel-mediated transmission in dopamine neurons. Neuropsychopharmacology 34: 1926-1935.
49. Ungless MA, Singh V, Crowder TL, Yaka R, Ron D, et al. (2003) Corticotropin-releasing factor requires CRF binding protein to potentiate NMDA receptors via CRF receptor 2 in dopamine neurons. Neuron 39: 401-407.
50. Riegel AC, Williams JT, (2008) CRF facilitates calcium release from intracellular stores in midbrain dopamine neurons. Neuron 57: 559-570.
51. Magalhaes AC, Holmes KD, Dale LB, Comps-Agrar L, Lee D, et al. (2010) CRF receptor 1 regulates anxiety behavior via sensitization of 5-HT2 receptor signaling. Nat Neurosci 13: 622-629.
52. Bale TL, (2005) Sensitivity to stress: dysregulation of CRF pathways and disease development. Horm Behav 48: 1-10.
53. Sarnyai Z, Shaham Y, Heinrichs SC, (2001) The role of corticotropin-releasing factor in drug addiction. Pharmacol Rev 53: 209-243.
54. Bale TL, Vale WW, (2004) CRF and CRF receptors: role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol 44: 525-557.
55. Tao J, Hildebrand ME, Liao P, Liang MC, Tan G, et al. (2008) Activation of corticotropin-releasing factor receptor 1 selectively inhibits CaV3.2 T-type calcium channels. Mol Pharmacol 73: 1596-1609.
56. Gutknecht E, Van der Linden I, Van Kolen K, Verhoeven KF, Vauquelin G, et al. (2009) Molecular mechanisms of corticotropin-releasing factor receptor-induced calcium signaling. Mol Pharmacol 75: 648-657.
57. Teli T, Markovic D, Levine MA, Hillhouse EW, Grammatopoulos DK, (2005) Regulation of corticotropin-releasing hormone receptor type 1alpha signaling: structural determinants for G protein-coupled receptor kinase-mediated phosphorylation and agonist-mediated desensitization. Mol Endocrinol 19: 474-490.
58. Lopez-Ilasaca M, Crespo P, Pellici PG, Gutkind JS, Wetzker R, (1997) Linkage of G protein-coupled receptors to the MAPK signaling pathway through PI 3-kinase gamma. Science 275: 394-397.
59. Dupre DJ, Robitaille M, Rebois RV, Hebert TE, (2009) The role of Gβγ subunits in the organization, assembly, and function of GPCR signaling complexes. Annu Rev Pharmacol Toxicol 49: 31-56.
60. Smrcka AV, (2008) G protein βγ subunits: central mediators of G protein-coupled receptor signaling. Cell Mol Life Sci 65: 2191-2214.
61. Tu H, Rondard P, Xu C, Bertaso F, Cao F, et al. (2007) Dominant role of GABAB2 and Gβγ for GABAB receptor-mediated-ERK1/2/CREB pathway in cerebellar neurons. Cell Signal 19: 1996-2002.
62. Akgoz M, Kalyanaraman V, Gautam N, (2006) G protein βγ complex translocation from plasma membrane to Golgi complex is influenced by receptor gamma subunit interaction. Cell Signal 18: 1758-1768.
63. Saini DK, Kalyanaraman V, Chisari M, Gautam N, (2007) A family of G protein βγ subunits translocate reversibly from the plasma membrane to endomembranes on receptor activation. J Biol Chem 282: 24099-24108.
64. Weick JP, Groth RD, Isaksen AL, Mermelstein PG, (2003) Interactions with PDZ proteins are required for L-type calcium channels to activate cAMP response element-binding protein-dependent gene expression. J Neurosci 23: 3446-3456.
65. Grove-Strawser D, Boulware MI, Mermelstein PG, (2010) Membrane estrogen receptors activate the metabotropic glutamate receptors mGluR5 and mGluR3 to bidirectionally regulate CREB phosphorylation in female rat striatal neurons. Neuroscience 170: 1045-1055.
66. Boulware MI, Kordasiewicz H, Mermelstein PG, (2007) Caveolin proteins are essential for distinct effects of membrane estrogen receptors in neurons. J Neurosci 27: 9941-9950.
67. Koob GF, (2010) The role of CRF and CRF-related peptides in the dark side of addiction. Brain Res 1314: 3-14.
68. Holahan MR, Kalin NH, Kelley AE, (1997) Microinfusion of corticotropin-releasing factor into the nucleus accumbens shell results in increased behavioral arousal and oral motor activity. Psychopharmacology (Berl) 130: 189-196.
69. Briand LA, Blendy JA, (2010) Molecular and genetic substrates linking stress and addiction. Brain Res 1314: 219-234.
70. Groth RD, Weick JP, Bradley KC, Luoma JI, Aravamudan B, et al. (2008) D1 dopamine receptor activation of NFAT-mediated striatal gene expression. Eur J Neurosci 27: 31-42.
71. Boulware MI, Weick JP, Becklund BR, Kuo SP, Groth RD, et al. (2005) Estradiol activates group I and II metabotropic glutamate receptor signaling, leading to opposing influences on cAMP response element-binding protein. J Neurosci 25: 5066-5078.
72. Pearce LR, Alton GR, Richter DT, Kath JC, Lingardo L, et al. (2010) Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochem J 431: 245-255.
73. Perrin MH, Donaldson CJ, Chen R, Lewis KA, Vale WW, (1993) Cloning and functional expression of a rat brain corticotropin releasing factor (CRF) receptor. Endocrinology 133: 3058-3061.
74. Facci L, Stevens DA, Pangallo M, Franceschini D, Skaper SD, et al. (2003) Corticotropin-releasing factor (CRF) and related peptides confer neuroprotection via type 1 CRF receptors. Neuropharmacology 45: 623-636.
75. Ruhmann A, Bonk I, Lin CR, Rosenfeld MG, Spiess J, (1998) Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): development of CRFR2beta-selective antisauvagine-30. Proc Natl Acad Sci U S A 95: 15264-15269.
76. Lawrence AJ, Krstew EV, Dautzenberg FM, Ruhmann A, (2002) The highly selective CRF(2) receptor antagonist K41498 binds to presynaptic CRF(2) receptors in rat brain. Br J Pharmacol 136: 896-904.
77. Glass DB, Lundquist LJ, Katz BM, Walsh DA, (1989) Protein kinase inhibitor-(6-22)-amide peptide analogs with standard and nonstandard amino acid substitutions for phenylalanine 10. Inhibition of cAMP-dependent protein kinase. J Biol Chem 264: 14579-14584.
78. Zheng XL, Matsubara S, Diao C, Hollenberg MD, Wong NC, (2000) Activation of apolipoprotein AI gene expression by protein kinase A and kinase C through transcription factor, Sp1. J Biol Chem 275: 31747-31754.
79. Farrow B, Rychahou P, Murillo C, O'Connor KL, Iwamura T, et al. (2003) Inhibition of pancreatic cancer cell growth and induction of apoptosis with novel therapies directed against protein kinase A. Surgery 134: 197-205.
80. Fu Y, Han J, Ishola T, Scerbo M, Adwanikar H, et al. (2008) PKA and ERK, but not PKC, in the amygdala contribute to pain-related synaptic plasticity and behavior. Mol Pain 4: 26.
81. Harris DN, Asaad MM, Phillips MB, Goldenberg HJ, Antonaccio MJ, (1979) Inhibition of adenylate cyclase in human blood platelets by 9-substituted adenine derivatives. J Cyclic Nucleotide Res 5: 125-134.
82. Freitag A, Wessler I, Racke K, (1998) Phosphodiesterase inhibitors suppress alpha2-adrenoceptor-mediated 5-hydroxytryptamine release from tracheae of newborn rabbits. Eur J Pharmacol 354: 67-71.
83. Thimmaiah KN, Easton JB, Germain GS, Morton CL, Kamath S, et al. (2005) Identification of N10-substituted phenoxazines as potent and specific inhibitors of Akt signaling. J Biol Chem 280: 31924-31935.
84. Groth RD, Mermelstein PG, (2003) Brain-derived neurotrophic factor activation of NFAT (nuclear factor of activated T-cells)-dependent transcription: a role for the transcription factor NFATc4 in neurotrophin-mediated gene expression. J Neurosci 23: 8125-8134.
85. Wasylyk C, Zheng H, Castell C, Debussche L, Multon MC, et al. (2008) Inhibition of the Ras-Net (Elk-3) pathway by a novel pyrazole that affects microtubules. Cancer Res 68: 1275-1283.
86. Tamura M, Nakao H, Yoshizaki H, Shiratsuchi M, Shigyo H, et al. (2005) Development of specific Rho-kinase inhibitors and their clinical application. Biochim Biophys Acta 1754: 245-252.
87. Yu JZ, Dave RH, Allen JA, Sarma T, Rasenick MM, (2009) Cytosolic Gα acts as an intracellular messenger to increase microtubule dynamics and promote neurite outgrowth. J Biol Chem 284: 10462-10472.
88. Kralisch S, Klein J, Lossner U, Bluher M, Paschke R, et al. (2005) Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes. J Endocrinol 185: R1-8.